CYP2C19 and *CES1* polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease

Brian L. Hoh, MD,¹ Yan Gong, PhD,² Caitrin W. McDonough, PhD,² Michael F. Waters, MD, PhD,³ Adrienne J. Royster, BSN,¹ Tiffany O. Sheehan, BSN,³ Ben Burkley, BS,² Taimour Y. Langae, PhD,² J Mocco, MD, MS,⁴ Scott L. Zuckerman, MD,⁴ Nishit Mummareddy, BS,⁴ Marcus L. Stephens II, MD,⁴ Christie Ingram, BS,⁵ Christian M. Shaffer, BS,⁵ Joshua C. Denny, MD, MS,⁵ Murray H. Brilliant, PhD,⁶ Terrie E. Kitchner,⁶ James G. Linneman, BA,⁷ Dan M. Roden, MD,^{5,8} and Julie A. Johnson, PharmD^{2,9}

Departments of ¹Neurosurgery and ³Neurology and ⁸Division of Cardiovascular Medicine, College of Medicine, and ²Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, Florida; and Departments of ⁴Neurosurgery, ⁵Medicine, and ⁶Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee; and ⁷Center for Human Genetics Research and ⁹Biomedical Informatics Research Center, Marshfield Clinic Research Foundation, Marshfield, Wisconsin

OBJECTIVE Symptomatic intracranial atherosclerotic disease (ICAD) has a high risk of recurrent stroke. Genetic polymorphisms in *CYP2C19* and *CES1* are associated with adverse outcomes in cardiovascular patients, but have not been studied in ICAD. The authors studied *CYP2C19* and *CES1* single-nucleotide polymorphisms (SNPs) in symptomatic ICAD patients.

METHODS Genotype testing for *CYP2C19**2, *3, *8, *17 and *CES1* G143E was performed on 188 adult symptomatic ICAD patients from 3 medical centers who were medically managed with clopidogrel and aspirin. Testing was performed prospectively at 1 center, and retrospectively from a DNA sample biorepository at 2 centers. Multiple logistic regression and Cox regression analysis were performed to assess the association of these SNPs with the primary endpoint, which was a composite of transient ischemic attack (TIA), stroke, myocardial infarction, or death within 12 months.

RESULTS The primary endpoint occurred in 14.9% of the 188 cases. In multiple logistic regression analysis, the presence of the *CYP2C19* loss of function (LOF) alleles *2, *3, and *8 in the medically managed patients was associated with lower odds of primary endpoint compared with wild-type homozygotes (odds ratio [OR] 0.13, 95% CI 0.03–0.62, $p = 0.0101$). Cox regression analysis demonstrated the *CYP2C19* LOF carriers had a lower risk for the primary endpoint, with hazard ratio (HR) of 0.27 (95% CI 0.08–0.95), $p = 0.041$. A sensitivity analysis of a secondary composite endpoint of TIA, stroke, or death demonstrated a significant trend in multiple logistic regression analysis of *CYP2C19* variants, with lower odds of secondary endpoint in patients carrying at least 1 LOF allele (*2, *3, *8) than in wild-type homozygotes (OR 0.27, 95% CI 0.06–1.16, $p = 0.078$). Cox regression analysis demonstrated that the carriers of *CYP2C19* LOF alleles had a lower risk for the secondary composite endpoint (HR 0.22, 95% CI 0.05–1.04, $p = 0.056$).

CONCLUSIONS This is the first study examining genetic variants and their effects in symptomatic ICAD. Variant alleles of *CYP2C19* (*2, *3, *8) were associated with lower odds of the primary and secondary composite endpoints. However, the direction of the association was opposite of what is expected based on this SNP. This may reflect an incomplete understanding of this genetic variation and its effect in symptomatic ICAD and warrants further investigations.

<http://thejns.org/doi/abs/10.3171/2015.6.JNS15795>

KEY WORDS antiplatelet; intracranial atherosclerotic disease; intracranial stenosis; stroke; pharmacogenomics; transient ischemic attack; vascular disorders

ABBREVIATIONS CES1 = carboxylesterase 1; CYP = cytochrome P450; ICAD = intracranial atherosclerotic disease; LOF = loss of function; MI = myocardial infarction; PTAS = percutaneous transluminal angioplasty and stenting; SAMMPRIS = Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis; SNP = single-nucleotide polymorphism; TIA = transient ischemic attack; WASID = Warfarin-Aspirin Symptomatic Intracranial Disease.

SUBMITTED April 8, 2015. **ACCEPTED** June 9, 2015.

INCLUDE WHEN CITING Published online November 20, 2015; DOI: 10.3171/2015.6.JNS15795.

SYMPTOMATIC intracranial atherosclerotic disease (ICAD) is the most common cause of stroke worldwide and is associated with a high risk of recurrent stroke.^{3,8} The results of the recently completed Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) trial suggest that aggressive medical management alone is superior to percutaneous transluminal angioplasty and stenting (PTAS) plus aggressive medical management in preventing stroke or death in patients with symptomatic ICAD.^{2,5} Even though the risk of stroke or death in the SAMMPRIS trial was lower than seen in the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial, this risk in either the PTAS group or the medically managed group is still unacceptably high, 23% in the PTAS group and 15% in the medically managed group.^{2,3,5}

In both the PTAS and the medical arms of the SAMMPRIS trial, patients were treated with aspirin and clopidogrel dual-antiplatelet therapy reflecting current management of symptomatic ICAD. Genetic polymorphisms in drug-metabolizing enzymes such as cytochrome P450 (CYP) 2C19 and carboxylesterase 1 (CES1) have been shown to affect the antiplatelet activity of clopidogrel^{11,14} and have been associated with increased risk of cardiovascular death, myocardial infarction (MI), or stroke in patients with acute coronary syndrome¹⁷ and patients undergoing percutaneous coronary interventions.¹⁵ It therefore seems possible that failure of aspirin and clopidogrel therapy in preventing stroke or death in symptomatic ICAD patients could be due to genetic polymorphisms that inhibit the antiplatelet activity of clopidogrel.

We conducted this study to test our hypothesis that polymorphisms in *CYP2C19* and *CES1* affect the efficacy of aspirin and clopidogrel dual-antiplatelet therapy in patients with symptomatic ICAD. This is the first study of which we are aware that examines genetic variants and their effects on the efficacy of clopidogrel in symptomatic ICAD.

Methods

Symptomatic ICAD patients taking clopidogrel and aspirin were studied from 3 centers: the University of Florida, Vanderbilt University, and Marshfield Clinic. This study was approved by the institutional review boards of all 3 institutions. The following inclusion criteria were used to enroll/identify patients: age 18 years or older, stroke or transient ischemic attack (TIA) attributable to 50% or greater stenosis of a major intracranial artery, and treatment with aspirin and clopidogrel for 3 months or longer. Patients with moyamoya disease were excluded from this study.

At one of the 3 centers (University of Florida), patients were prospectively enrolled, and DNA samples were prospectively collected. At the other 2 centers (Vanderbilt University and Marshfield Clinic), patients were retrospectively identified from the electronic medical record using an ICD-9–based algorithm, followed by manual review of the electronic charts of each of the patients to verify accuracy, and DNA samples were obtained from a biorepository of stored patient samples.

Patients provided a sample of either saliva or blood. Pa-

tient samples from the University of Florida were genotyped at the University of Florida through the Sequenom, pyrosequencing (Qiagen) or Taqman (Life Technologies) genotyping method for the following variants: *CYP2C19**2 (rs4244285, G > A), *CYP2C19**3 (rs4986893, G > A), *CYP2C19**8 (rs41291556, T > C), *CYP2C19**17 (rs12248560, G > A), and *CES1* G143E (rs71647871, G > A).

Patient samples from Vanderbilt University and Marshfield clinic were genotyped at Vanderbilt University by the Vanderbilt Technologies for Advanced Genomics core with a combination of TaqMan Assay (rs12248560) and the Sequenom genotyping platform (rs4244285, rs4986893, rs41291556, rs71647871, rs12041331, rs662, rs854560). Genotyping efficiency was 100% in all samples, and genotypes conformed to expectations under Hardy-Weinberg equilibrium. Quality control also included inter- and intraplate replicate samples and HapMap controls showing 100% concordance and zero Mendelian errors.

The primary endpoint was a predefined composite of TIA, stroke, myocardial infarction, or death within 12 months of beginning clopidogrel. A sensitivity analysis of a secondary composite endpoint of TIA, stroke, or death within 12 months of beginning clopidogrel was also performed. Patients who were treated with PTAS and patients treated medically were analyzed separately, as we would expect a different rate of the primary endpoint between the 2 groups based on previous studies.^{2,5} After identification/enrollment of patients and collection of samples, the number of patients in the PTAS group with an event was too low to allow for meaningful conclusions. Therefore, PTAS-treated patients were excluded and only medically managed patients were included.

Statistical Analysis

Hardy-Weinberg equilibrium was evaluated within race/ethnicity using chi-square tests with 1 degree of freedom. *CYP2C9* polymorphisms *2, *3, and *8 were combined for the number of loss of function (LOF) alleles (0, 1, or 2). Due to the low number of individuals with 2 copies of LOF alleles, patients with 1 or 2 copies of LOF alleles were combined as LOF allele carriers. Due to the functional basis of these variants, we performed the association analysis in the combined data set, adjusting for the race group. Multiple logistic regression was performed to assess the association of *CYP2C19* polymorphisms or *CES1* G143E genotype and the primary endpoint (the occurrence of TIA, stroke, myocardial infarction, or death within 12 months of initiation of clopidogrel therapy) and the secondary endpoint (the occurrence of TIA, stroke, or death within 12 months of initiation of clopidogrel therapy) adjusting for covariates: site, age, sex, race, hypertension, diabetes, taking lipid-lowering medication, and taking a proton pump inhibitor. A Kaplan-Meier curve was constructed by *CYP2C19* LOF carrier status, and log-rank tests were performed to compare time to event by the carrier status. Multivariable Cox regression analysis was performed to assess the time to the primary and secondary endpoint. The covariates adjusted in the Cox regression analysis were the same as those used in the logistic regression analysis; p values < 0.025 were considered statistically significant because 2 genes were examined. All statistical analyses were performed in SAS 9.2.

Results

A total of 188 medically managed patients were included in the study. Their baseline demographic characteristics are presented in Table 1. The patients had an average age of 67 years; 63.3% were males and more than 84% were white. Of the 188 patients, 92.6% had a history of hypertension, and 93.1% were treated with lipid-lowering medications, while about 58% were taking a proton pump inhibitor.

The primary endpoint (TIA, stroke, MI, death) occurred in 14.9% of medically treated patients (28/188) (Table 2). The secondary endpoint (TIA, stroke, death) occurred in 11.2% of medically treated patients (21/188) (Table 2). The remainder of the patients did not have an event within the first 12 months after initiation of clopidogrel treatment.

The genotype frequencies of the single-nucleotide polymorphisms (SNPs) did not deviate from Hardy-Weinberg equilibrium when tested with the patients stratified by race or as a single group (all *p* values > 0.05). The allele frequencies of the 5 SNPs are shown in Table 3. In all the studied patients, 1 heterozygote for *CYP2C19**3 and 1 heterozygote for *8 were observed. The allele frequencies for *CYP2C19**2, *CYP2C19**17, and *CES1* G143E were 14%, 21%, and 0.017%, respectively, consistent with those reported in the 1000 genomes project. Due to the low allele frequency of *CYP2C19**3 and *8, the number of *CYP2C19* LOF alleles was calculated, combining these 2 variants with the *2 variant. Twenty-seven percent of the participants had 1 or 2 LOF *CYP2C19* alleles.

In the unadjusted analysis, none of the SNPs reached statistical significance (data not shown). After adjusting for covariates, in multiple logistic regression analysis, carriers of *CYP2C19* LOF alleles *2, *3, *8 had lower odds of the primary endpoint in the medical group compared with wild-type homozygotes (OR 0.13, 95% CI 0.03–0.62, *p* = 0.01) (Table 4). A Kaplan-Meier curve by *CYP2C19* LOF carrier status is shown in Fig. 1 (upper). The log-rank *p* value was 0.059.

Cox regression analysis showed that after adjusting for covariates, the risk for the primary endpoint was lower in the carriers of at least one *CYP2C19* LOF allele compared with those with wild-type homozygotes, with a hazard ratio of 0.27 (95% CI 0.08–0.95, *p* = 0.041). The number of events in the PTSA group was too small to estimate the odds ratios and hazard ratios; therefore PTSA-treated patients were excluded from the analysis. A sensitivity analysis was performed of a secondary composite endpoint of TIA, stroke, or death. After adjusting for covariates, in multiple logistic regression analysis, carriers of *CYP2C19* LOF alleles *2, *3, *8 had lower odds of the secondary composite endpoint in the medical group compared with wild-type homozygotes (OR 0.27, 95% CI 0.06–1.16, *p* = 0.078) (Table 5). Cox regression analysis demonstrated that the *CYP2C19* LOF carriers had a lower risk for the secondary composite endpoint, with a hazard ratio of 0.22 (95% CI 0.05–1.04, *p* = 0.056).

A secondary analysis was performed excluding one of the retrospective centers (Vanderbilt) because the incidence of the endpoints at that center was disparate from the other 2 centers (University of Florida and Marshfield), which had very similar incidences of the endpoints. The

TABLE 1. Baseline demographic characteristics of 188 patients treated with medical management in 3 centers

Characteristics	Value
Age (years), mean ± SD	67.0 ± 12.2
Male sex	119 (63.3)
Race/ethnicity	
White	159 (84.6)
Black	24 (12.8)
Other	5 (2.7)
History of smoking	109 (58)
History of hypertension	174 (92.6)
Diabetes	88 (46.8)
Taking a lipid-lowering drug	175 (93.1)
Taking a proton pump inhibitor	109 (58)

* Data represented as number (%) unless stated otherwise.

secondary analysis included 93 patients, and the results were largely similar to the analysis that included all 3 centers. Multivariable logistic regression analysis demonstrated that the LOF variant alleles of *CYP2C19* (*2, *3, *8) were associated with lower odds of primary endpoint in the medical group compared with wild-type homozygotes (OR 0.17, 95% CI 0.04–0.82, *p* = 0.0273). The Kaplan-Meier curve by *CYP2C19* LOF allele carrier status is shown in Fig. 1 (lower). The log-rank *p* value was 0.0502. The adjusted hazard ratio for the primary endpoint was 0.23 (95% CI 0.06–0.85, *p* = 0.0268) for *CYP2C19* LOF carriers compared with those with no LOF alleles.

Discussion

This is the first study of which we are aware that examines genetic variants and their effects on the efficacy of clopidogrel in symptomatic ICAD. In our group of medically treated patients, the *2, *3, *8 variant alleles of *CYP2C19* were associated with lower odds of the primary endpoint (TIA, stroke, myocardial infarction, or death within 12 months of beginning clopidogrel) and the secondary endpoint (TIA, stroke, or death within 12 months of beginning clopidogrel) in symptomatic ICAD patients treated with aspirin and clopidogrel. However, this finding is antithetical to what we would expect for these variant alleles, which are LOF alleles; the expected finding would be higher odds of the primary and secondary endpoint. The direction of this correlation was unexpected given the well-known association between *CYP2C19* genetic variation and increased risk of cardiovascular death, MI, or stroke in acute coronary syndrome patients¹⁷ and percutaneous coronary intervention patients.¹⁵ In terms of cerebrovascular disease, *CYP2C19* polymorphisms seem to correlate with 3-month and 6-month modified Rankin Scale outcomes in Chinese stroke patients, although ICAD and the risk of recurrent stroke have not been specifically examined until this present study.¹⁰ Additionally, there may be an association between *CYP2C19* LOF genotypes and in-stent restenosis in Chinese patients treated with vertebral artery stenting.¹² More than 25 variant alleles have been reported for the *CYP2C19* gene. *CYP2C19**2, *3, and *8 are all LOF alleles, and *CYP2C19**17 is a gain-of-func-

TABLE 2. Events in 188 medically managed patients

Event	UF (n = 28)	Vanderbilt (n = 120)	Marshfield (n = 40)	Total (n = 188)
TIA	6	0	4	10
Stroke	2	4	1	7
MI	0	2*	7	9
Death	2	2	2	6
Composite of TIA, stroke, MI, death	8	6*	14	28
Composite of TIA, stroke, death	8	6	7	21

UF = University of Florida.

* The 2 patients at Vanderbilt who had an MI also had stroke.

tion allele. The *CYP2C19**2 SNP (rs4244285, G681A) in exon 5 results in a splice defect; *CYP2C19**3 (rs4986893, G > A) in exon 4 produces a stop codon; *CYP2C19**8 (rs41291556, T > C), a change of Trp120Arg in exon 3 that affects the catalytic activity of the CYP2C19 enzyme; and the gain-of-function *CYP2C19**17 (rs12248560, G > A), which affects the promoter region, increases the *CYP2C19* gene expression level.^{1,4,6,7,9}

There are many possible explanations for our observed findings. First, the heterogeneity of the various ways ICAD can lead to stroke or TIA, in comparison with coronary atherosclerotic disease, could suggest that features of ICAD differ from coronary atherosclerosis, and we may not observe the same findings in the 2 disease states.¹³ Second, it is possible that clopidogrel is not efficacious in preventing stroke in ICAD, and that the observed results in medically managed patients are due to other interventions, such as statin therapy, blood pressure reduction, smoking cessation, and diabetes management. Other studies, such as those in patients with atrial fibrillation receiving clopidogrel, have shown a lack of the expected genetic effect when the overall efficacy of the drug is lacking.¹⁶ Finally, it is important to note that our sample size in this study is relatively small, and the observed findings could be due to chance and lack of power to detect a true genetic effect.

Our analysis adjusted for a number of covariates, including factors that are known to affect clopidogrel response, such as proton pump inhibitor use, and factors that affect event rate such as hypertension.

Our results did not show an association between genetic variants of *CES1* and the primary endpoint. Carboxylesterase 1 is a serine esterase that is the primary enzyme responsible for metabolizing clopidogrel, its intermediate metabolite (2-oxo-clopidogrel), and the final bioactive thiol metabolite into biologically inactive carboxylic acid derivatives.¹¹ The G > A (rs71647871) variation in exon 4 of *CES1* results in a nonconservative substitution,

p.Gly143Glu, and in vitro functional studies have shown that the catalytic function of p.Gly143Glu is substantially impaired, resulting in a complete loss of hydrolytic activity of carboxylesterase 1 toward methylphenidate.¹⁸ Thus, the expected effect of *CES1* G143E (rs71647871, G > A) polymorphism would be that it would cause reduced degradation of clopidogrel, leading to more of the drug being available to go down the bioactivation pathway, leading to enhanced antiplatelet activity of clopidogrel.¹¹ There have been no prior studies examining *CES1* G143E (rs71647871, G > A) polymorphism and clopidogrel efficacy in cardiovascular or stroke patients, thus the non-association may reflect an incomplete understanding of the clinical effects of *CES1* genetic variation in cardiovascular disease and stroke, and warrants further investigation. Nevertheless, due to the very low incidence of *CES1* genetic variation, our study was unable to demonstrate an association with *CES1* variants and the primary and secondary composite endpoints.

Our study highlights the disparity in findings from a prospective study contrasted with a retrospective analysis from electronic medical records. One of the centers in this study (Vanderbilt), which conducted a retrospective analysis of data from electronic medical records, had incidences of the clinical endpoints that were significantly lower than expected for the natural history of the disease.^{2,3} The incidence of the clinical endpoints at this center was significantly different than at the other 2 centers, which had similar incidences for the endpoints. This was the reason we conducted a secondary analysis excluding this center. We believe this highlights a significant limitation of retrospective analysis for these types of studies. There has recently been great interest in genotypic and comparative analysis studies from electronic medical records. This enthusiasm for “big data” has led to significant interest in capturing clinical data from large electronic medical databases using billing and procedure codes. The advantage of

TABLE 3. Minor allele frequencies of the SNPs tested

Chromosome	SNP	rs No.	Alleles (major/minor)	Minor Allele Frequency			
				White	Black	Other	Overall
10	<i>CYP2C19</i> *2	rs4244285	C/T	0.14	0.14	0.43	0.14
10	<i>CYP2C19</i> *3	rs4986893	G/A	0	0.015	0	0.002
10	<i>CYP2C19</i> *8	rs41291556	T/C	0.0026	0	0	0.002
10	<i>CYP2C19</i> *17	rs12248560	C/T	0.21	0.14	0.14	0.21
16	<i>CES1</i> G143E	rs71647871	G/A	0.016	0.015	0.14	0.017

TABLE 4. Multiple logistic regression analysis results of the SNPs associated with the primary composite endpoint of TIA, stroke, MI, and death at all 3 centers*

SNP	OR	95% CI	p Value
Carrier of <i>CYP2C19</i> LOF allele (*2, *3, or *8)	0.13	0.03–0.62	0.01
<i>CYP2C19</i> *17	0.94	0.39–2.28	0.89
<i>CES1</i> G143E	5.54	0.63–49.03	0.12

* The p values were adjusted for age, sex, race, site, hypertension, diabetes, taking lipid-lowering medication, and taking a proton pump inhibitor. The ORs in the PTAS group were not estimable due to low numbers.

these studies is the ability to capture large amounts of patient data across many centers. Many studies use an ICD-9-code-based query for the identification of patients and data, much like what was conducted at two of the centers in our study (Vanderbilt and Marshfield). In performing this study, however, we were clearly more confident in the ability in the prospective arm of the study to accurately identify patients who appropriately qualified according to all inclusion and exclusion criteria and the ability to accurately adjudicate clinical endpoints than in the retrospective arms of the study. We believe that this is a strong argument for funding and conducting prospective studies and a cause for cautionary concern regarding analysis of data from electronic medical records databases.

The combining of prospective data from 1 center with retrospective data from 2 centers was necessary to achieve an adequate sample size based on our prestudy power analysis. We took advantage of the biorepositories already established at two of the centers via the Pharmacogenomics Research Network (PGRN). However, there are obvious limitations of combining prospective data with retrospective data. Our finding of disparate incidences of the endpoints at one of the retrospective centers demonstrates some of the shortcomings of retrospective data collection and analysis. There has been great enthusiasm for comparative effectiveness research utilizing electronic medical records and “big data.” However, we feel that our study highlights the limitations of retrospective electronic capture of clinical data, which we believe does not match the scientific rigor of prospective enrollment and analysis. Therefore, we believe that it is critical to fund and implement prospective studies to address these questions.

In this study, we did not collect and analyze functional assays such as platelet function tests, platelet aggregation studies, thromboelastography, or P2Y₁₂ receptor tests. The DNA samples from the 2 retrospective centers were collected from established biorepositories; thus the performance of platelet function assays was not possible. There are limitations of such platelet function tests such as the proper timing of these tests, variability among testing sites, and variability in interpretation. Nevertheless, in future investigations, it would be interesting to study the association of pharmacogenomic variations with these functional platelet assays.

Conclusions

While the findings of the recently completed SAMM-

CYP2C19 LOF alleles and Primary Endpoint

CYP2C19 LOF alleles and Primary Endpoint (2 centers)

FIG. 1. Kaplan-Meier curves for the medically treated patients stratified by *CYP2C19* loss of function (LOF) allele status in all 3 centers (upper) and 2 centers (lower).

PRIS trial^{2,5} suggest that medical management is superior to PTAS for patients with symptomatic ICAD, there are still subgroups of patients at unacceptably high risk of recurrent stroke despite aggressive medical management. Since the medical management of symptomatic ICAD is aspirin and clopidogrel dual antiplatelet therapy, it seems quite possible that patients with genetic variants predisposing to reduced antiplatelet efficacy of clopidogrel may be at higher risk of recurrent stroke. Defining these genetic variants and their association with the clinical efficacy of clopidogrel is important to the development of personalized therapeutic strategies for these high-risk patients. The findings of this study are a first step, and while we found

TABLE 5. Multiple logistic regression analysis results of the SNPs associated with the secondary composite endpoint of TIA, stroke, and death at all 3 centers

SNP	OR	95% CI	p
Carrier of <i>CYP2C19</i> LOF allele (*2, *3, or *8) combined)	0.27	0.06–1.16	0.078
<i>CYP2C19</i> *17	1.95	0.77–4.93	0.16
<i>CES1</i> G143E	8.25	0.94–72.08	0.056

that *CYP2C19**2, *3, and *8 were associated with lower odds of the primary and secondary endpoints in the medical group compared with wild-type homozygotes, we do not completely understand this relationship or the mechanism of action. Due to the low incidence of *CES1* genetic variation, our study was unable to demonstrate any association between *CES1* variations and the primary and secondary endpoints. Further, larger-scale, prospective multicenter studies will be necessary to better elucidate these questions.

Acknowledgments

This study was funded by NIH U19 HL065962, NIH U01 GM074492, and the University of Florida Research Foundation.

References

1. Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, et al: Identification and functional characterization of new potentially defective alleles of human CYP2C19. *Pharmacogenetics* **12**:703–711, 2002
2. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al: Stenting versus aggressive medical therapy for intracranial arterial stenosis. *N Engl J Med* **365**:993–1003, 2011
3. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. *N Engl J Med* **352**:1305–1316, 2005
4. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. *J Biol Chem* **269**:15419–15422, 1994
5. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, et al: Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. *Lancet* **383**:333–341, 2014
6. Desta Z, Zhao X, Shin JG, Flockhart DA: Clinical significance of the cytochrome P450 2C19 genetic polymorphism. *Clin Pharmacokinet* **41**:913–958, 2002
7. Goldstein JA, Blaisdell J: Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. *Methods Enzymol* **272**:210–218, 1996
8. Gorelick PB, Wong KS, Bae HJ, Pandey DK: Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. *Stroke* **39**:2396–2399, 2008
9. Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, et al: A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. *J Pharmacol Exp Ther* **290**:635–640, 1999
10. Jia DM, Chen ZB, Zhang MJ, Yang WJ, Jin JL, Xia YQ, et al: CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. *Stroke* **44**:1717–1719, 2013
11. Lewis JP, Horenstein RB, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, et al: The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. *Pharmacogenet Genomics* **23**:1–8, 2013
12. Lin YJ, Li JW, Zhang MJ, Qian L, Yang WJ, Zhang CL, et al: The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment. *CNS Neurosci Ther* **20**:125–130, 2014
13. López-Cancio E, Matheus MG, Romano JG, Liebeskind DS, Prabhakaran S, Turan TN, et al: Infarct patterns, collaterals and likely causative mechanisms of stroke in symptomatic intracranial atherosclerosis. *Cerebrovasc Dis* **37**:417–422, 2014
14. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al: Cytochrome p-450 polymorphisms and response to clopidogrel. *N Engl J Med* **360**:354–362, 2009
15. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al: Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. *JAMA* **304**:1821–1830, 2010
16. Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, et al: Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. *N Engl J Med* **363**:1704–1714, 2010
17. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al: Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. *Lancet* **376**:1320–1328, 2010
18. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, et al: Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. *Am J Hum Genet* **82**:1241–1248, 2008

Disclosures

Dr. Mocco reports consultant relationships with Lazarus Effect, Reverse, Pulsar Edge Therapeutics, and Medina; an investor relationship with Blockade Medical; and being on the advisory board for Codman Neurovascular.

Author Contributions

Conception and design: Hoh, McDonough, Waters, Johnson. Acquisition of data: Hoh, Waters, Royster, Sheehan, Burkley, Mocco, Zuckerman, Mummareddy, Stephens, Ingram, Shaffer, Denny, Brilliant, Kitchner, Linneman, Roden, Johnson. Analysis and interpretation of data: Hoh, Gong, McDonough, Langae, Johnson. Drafting the article: Hoh. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Hoh. Statistical analysis: Gong, Administrative/technical/material support: Hoh, Royster, Sheehan, Burkley, Ingram, Shaffer, Denny, Brilliant, Kitchner, Linneman, Roden, Johnson. Study supervision: Hoh.

Correspondence

Brian L. Hoh, Department of Neurosurgery, University of Florida College of Medicine, P.O. Box 100265, Gainesville, FL 32610. email: brian.hoh@neurosurgery.ufl.edu.